Loading...
Loading...
ACET| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 1.8M |
| Gross Profit | -1.8M |
| Operating Expense | 33.3M |
| Operating I/L | -33.3M |
| Other Income/Expense | 2.4M |
| Interest Income | 2.7M |
| Pretax | -30.9M |
| Income Tax Expense | -1.3M |
| Net Income/Loss | -29.6M |
Adicet Bio, Inc. is a biotechnology company specializing in the discovery and development of allogeneic gamma delta T cell therapies for cancer and other diseases. The company's revenue is generated through the offering of gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies, which enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. Their lead product, ADI-001, is in Phase I clinical study for non-Hodgkin's lymphoma treatment, and they are also developing ADI-002 for various solid tumors.
